Ibrahim Osama Elnahal

Experienced Medical Manager with the following key executive highlights:

• Academic Background:
• clinical pharmacist with 2 MSc degrees in:

Advanced clinical Pharmacy Practice Professional PharmD

• Professional Background:

15 years in pharmaceutical field.

9 years in medical affairs

• TA Background:

6 years in Diabetes & Metabolic

5 years in Oncology & Hematology

4 years in Immunology & Diversified

• Geographical Background:

13 years for Saudi Arabia

2 years for GCC

2 years for Egypt

• Official Assignments above role:

2 years Medical Regional Lead, MEAR "Middle East Africa & Russia"

2 years Medical Operation & Excellence lead for Saudi Arabia

ACCOMPLISHMENTS | INTERNAL STAKEHOLDERS

• Medical Operations and Excellence Lead for Saudi Arabia - Above role assignment (AbbVie, 2025)
• Experience in managing/handling Audit inquiries (internal & external audits) (AbbVie, 2024-2025)
• Medical Regional Lead for MEAR "Middle East, Africa & Russia", (AbbVie) - Dermatology, 2023 & Oncology 2025
• Reviewing and updating SOPs “Promotional and non-promotional materials review” (AbbVie, 2023)
• Veeva Vault champion (AbbVie, 2022-2023)
• MENA assignment for medical pre-launch readiness for Oncology portfolio in alignment with central marketing team (Hikma, 2021)
• Medical assessment for potential biotechnology molecules in alignment with business development team (Hikma, 2020)
• Preparing scientific newsletter for different therapeutic areas; Breast cancer, Lymphomas, COVID19 vaccines and treatment program etc. (Hikma, 2020)
• Promotional materials review “Zinc, Veeva”: providing medical reports for several meetings “Advisory boards, Conferences, etc.” (MSD, 2019-2020)
• Launching an initiative for medical training SMS project “Short Medical Sessions” with new digital way for engaging participants. Description: Creating MCQs by using Kahoot application, which allows participants to interact by using their smart devices in a competitive way (MSD, 2017)
• Preparing training material for Evidence Based Medicine (Clinical trials designs & Results interpretation) and conducting training for all MSD medical rep. and 1st line managers in collaboration with Learning & Development team (MSD, 2017)
• Creating medical booklet (Etoricoxib Product Guide) for internal use among primary care sales team in MSD (was recognized by global medical and marketing directors for diversified brands) (MSD, 2016)
• Medical Assignment before promotion: Preparing Medical file approved by Medical Affairs Department – MSD Saudi Arabia and distributed to sales team across kingdom in Diabetes Business Unit (Clinical Trials Summary of Sitagliptin) (MSD, 2016)

ACCOMPLISHMENTS | EXTERNAL STAKEHOLDERS

• Experience in handling SFDA medical inquires/drug Appeal throughout drug registration journey in alignment with different internal stakeholders like RA (AbbVie, 2024-2025)
• Experience in leading/executing regional medical events across MEAR "Middle East, Africa & Russia" (AbbVie, 2023-2025)
• Arranging and conducting several Ad board meetings and preceptorship programs across GCC in the fields of oncology, Hematology and Immunology; both national and regional levels (MSD, Hikma, AbbVie, 2017-2024)
• Arranging and conducting Meet the Expert forums in parallel to international congresses by engaging top Saudi experts and international experts (AbbVie, 2021-2023)
• Data generation for both interventional and observational studies; phase III and phase IV (MSD, AbbVie, 2018-2024)
• Co-author in a local study, DYSIS II Saudi Arabia with engaging 4 centers in the study – Published by SMJ ‘Saudi Medical Journal' Saudi Med J. 2018 Jul;39(7):697-704. Doi: 10.15537/smj.2018.7.22146 Available online at: https://www.ncbi.nlm.nih.gov/pubmed/29968891 (MSD, 2018)
• Participating in and organizing +10 Regional SASS “Standalone Scientific Symposium” (MSD, AbbVie, 2017-2022)
• Organizing +10 local SASS “Standalone Scientific Symposium” (MSD, Hikma, AbbVie, 2017-2023)
• Arranging and conducting Center of Excellence programs in collaboration with reputable European centers as long-term partnership programs (AbbVie, 2022)
• Invest In the Heart initiative: communicating Interventional cardiologists in CCUs “Cardiac Care Units” with the role of non-statin agents for ACS patients “Acute Coronary Syndrome” and its clinical implication in admission protocols or discharge letters (MSD, 2017)
• LABTarget initiative: working with departmental heads “Endocrinologists & Cardiologists” and in alignment with laboratory director in each center to amend LDL-C “Lipid values references” as per recent guidelines (MSD, 2017)